Argan Inc. (AGX) Drops 6.09% on January 07

Equities Staff |

Argan Inc. (AGX) was one of the Russell 2000's biggest losers for Thursday January 07 as the stock slid 6.09% to $30.36, a loss of $-1.97 per share. Starting at an opening price of $31.70 a share, the stock traded between $30.20 and $31.83 over the course of the trading day. Volume was 89,088 shares over 980 trades, against an average daily volume of 147,099 shares and a total float of 14.83 million.

The losses send Argan Inc. down to a market cap of $450.13 million. In the last year, Argan Inc. has traded between $42.50 and $29.63, and its 50-day SMA is currently $35.82 and 200-day SMA is $36.14.

The stock has a P/E Ratio of 13.7.

Argan Inc through its subsidiaries provides development, consulting, engineering, procurement, construction, commissioning, operations and maintenance services to the power generation and renewable energy markets.

Argan Inc. is based out of Rockville, MD and has some 862 employees. Its CEO is William F. Griffin / Rainer H. Bosselmann.

For a complete fundamental analysis analysis of Argan Inc., check out’s Stock Valuation Analysis report for AGX. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

PixarBio Corp

PixarBio Corp is a specialty pharmaceutical/biotechnology company focused on pre-clinical and commercial development of novel neurological drug delivery systems for post-operative pain.

Private Markets


Uber connects riders with safe, reliable, convenient transportation providers at a variety of price-points in cities around the world. Uber makes money from charging their drivers 20% of the fare…


A peer-to-Peer authentic photo marketplace disrupting the $10B commercial photography industry.